Koen Deloose (AZ Sint Blasius Hospital, Dendermonde, Belgium) presented new sub-cohort analyses from the TINTIN trial at this year’s Leipzig Interventional Course (LINC 2025; 28–30 January, Leipzig, Germany), offering deeper insights into the long-term outcomes for different types of patients.
An iVascular press release reports that the trial—with 100 patients enrolled and after five-year follow-up—has consistently demonstrated the effectiveness of combining the Luminor drug-coated balloon (DCB) with the self-expandable iVolution Pro stent for the treatment of long and complex femoropopliteal lesions.
The combination therapy demonstrated strong durability over a five-year follow-up period, with a freedom from target lesion revascularisation (fTLR) rate of 62.5%. This translates to only four out of 10 patients requiring reintervention after five years.
Further subsanalyses revealed no significant differences in survival rates or fTLR outcomes across diabetic and non-diabetic patients, occluded and non-occluded lesions, or varying TASC classifications. The only notable differentiation was in the survival rates between chronic limb-threatening ischaemia (CLTI) and non-CLTI patients.
iVascular notes that these findings underscore the success of the ‘TINTIN technique’, defined by Deloose as the combination of Luminor DCB and iVolution Pro for long and complex femoropopliteal lesions with an average length of 242mm and all classified as TASC C or D.
Deloose, who is principal investigator of TINTIN, reflects on these latest results: “The combination of the Luminor DCB and iVolution Pro [self-expandable] as the TINTIN technique was a no-brainer for me, given the extensive data and evidence supporting its efficacy in treating the most complex femoropopliteal lesions.”
